See More

See the difference

See the difference

Aspaveli provides a superior increase in Hb vs eculizumab in patients with persistent anaemia despite C5i treatment1

Aspaveli was superior to eculizumab in improving Hb levels from baseline to Week 16 (P<0.0001)1

mean difference between Aspaveli and eculizumab

Primary endpoint analysis of the PEGASUS data is censored for transfusion. Transfusions could confound the results, so data after the first transfusion for all patients were not included in the primary analysis. Post-transfusion data were omitted once they had a transfusion and their data were modelled out for the remainder of the 16-week randomised control period.1,2

The between-group comparison for the primary end point was performed with the use of a mixed-effect model for repeated measures, with baseline hemoglobin as a continuous variable, time point as a categorical variable, and treatment group, stratification variables, and time-bytreatment interaction as fixed effects.1

CI=confidence interval; Hb=haemoglobin; SE=standard error.

References: 1. Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384:1028–1037. 2. Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(suppl):1–16.